论文部分内容阅读
目的探讨卡培他滨联合草酸铂治疗晚期结肠癌的临床疗效。方法 59例晚期结肠癌患者,将其按照用药方案的不同分为观察组(30例)和对照组(29例)。观察组实施卡培他滨联合草酸铂治疗,对照组患者单纯采取卡培他滨治疗,对比两组患者的治疗效果以及不良反应发生率。结果观察组治疗总有效率为86.7%;对照组为55.2%,观察组治疗总有效率优于对照组(P<0.05);观察组不良反应总发生率均显著低于对照组,差异有统计学意义(P<0.05)。结论卡培他滨联合草酸铂治疗晚期结肠癌的临床疗效显著,药物安全性高,有利于改善患者预后,可在临床广泛应用。
Objective To investigate the clinical efficacy of capecitabine combined with oxaliplatin in the treatment of advanced colon cancer. Methods Fifty-nine patients with advanced colon cancer were divided into observation group (n = 30) and control group (n = 29) according to the dosage regimen. The observation group was treated with capecitabine combined with oxaliplatin, and the control group was treated with capecitabine alone. The therapeutic effect and the incidence of adverse reactions were compared between the two groups. Results The total effective rate was 86.7% in the observation group and 55.2% in the control group, and the total effective rate in the observation group was better than that in the control group (P <0.05). The total adverse reaction rate in the observation group was significantly lower than that in the control group Significance (P <0.05). Conclusion Capecitabine combined with oxaliplatin in the treatment of advanced colorectal cancer has significant clinical efficacy, high drug safety, which is beneficial to improve the prognosis of patients and can be widely used clinically.